Navigation Links
Effective pain treatment for cancer patients?
Date:6/25/2009

Cancer patients often suffer from severe pain that cannot be effectively treated with conventional medication. Researchers at the Pharmacology Institute of the University of Heidelberg have found the possible reasons for this tumors release two signal substances that make nerve cells especially sensitive and enhance tumor growth. In animal tests, when the researchers blocked the effect of the signal substances on the nerve cells, the sensitivity of the nerve cells and tumor growth were reduced.

The results of the research of the international working group headed by Professor Dr. Rohini Kuner indicate a new approach for the development of effective pain medication for cancer patients. The work has now been published online in the prestigious journal Nature Medicine.

Tumor pain: new therapies are urgently needed

For patients, severe pain is one of the worst and most feared symptoms of cancer. The causes of the frequently extreme pain are still largely unknown. Cancer pain is frequently difficult to handle with conventional pain medication such as opioids. High dosages are required to achieve any effect at all as a result, the side effects are immense for the patients and tolerance may quickly ensue. "There is a great need for special pain medication for cancer patients," says pharmacologist Professor Dr. Rohini Kuner, who is especially interested in explaining the mechanisms of chronic pain.

Tumor signals make nerve cells extremely sensitive to pressure

In this research project, she and her colleagues examined tissue from mice to determine what signal substances were released by tumors. They discovered two molecules that were previously known only as growth factors for blood-forming stem cells. Contact with these molecules made nerve cells in the vicinity of the cancer tissue considerably more sensitive to pressure, as the researchers demonstrated by testing nerve activity with electrodes. "The findings are consistent with descriptions of cancer patients who say that merely touching the affected area is painful," explained Professor Dr. Kuner.

But not just touching, even tumor growth itself causes pain, for the expanding tissue also exerts pressure. The cancer cells apparently use the growth factors for their own growth and spread through the nerve pathways and blood vessels to the rest of the organism.

An injection against tumor pain?

The discovery made in Heidelberg opens up new prospects in the fight against cancer pain in the next step, the researchers injected proteins (antibodies) that block the contact sites for cancer signal substances on the nerve cells. Indeed, the sensitivity of nerve cells and tumor growth were reduced.

Further research must now show whether this use is also possible in human tissue. If so, it would be conceivable to inject these "protein blockers" directly into the tumor and thus reduce pain and side effects for the patient.


'/>"/>

Contact: Dr. Rohini Kuner
rohini.kuner@pharma.uni-heidelberg.de
49-622-154-8289
University Hospital Heidelberg
Source:Eurekalert  

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
4. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
7. Case Management Cost-Effective Way to Cut Heart Risks
8. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
9. Nasal Anthrax Vaccine Proves Effective in Animal Study
10. Family-based treatment more effective than supportive psychotherapy in treating bulimia
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Effective pain treatment for cancer patients?
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: